title: Tachykinins and kinins in antigen-evoked plasma extravasation in guinea-pig nasal mucosa.
abstract: The plasma extravasation evoked by instillation of 5% ovalbumin in the nasal mucosa of sensitized guinea-pigs was potentiated by the neutral endopeptidase inhibitor, phosphoramidon, and was reduced by the tachykinin NK1 receptor antagonist, CP-96,345. The bradykinin B2 receptor antagonist, HOE 140, also reduced the plasma extravasation evoked by the antigen. The combination of HOE 140 and CP-96,345 did not increase further the inhibition caused by HOE 140 alone. Plasma extravasation evoked by instillation of capsaicin was abolished by CP-96,345. HOE 140 blocked and CP-96,345 markedly reduced plasma extravasation caused by instillation of bradykinin. Plasma extravasation evoked by instillation of substance P was not affected by HOE 140. We conclude that antigen challenge causes plasma extravasation in the nasal mucosa of sensitized guinea-pigs, an effect that is due in part to the release of tachykinins from sensory nerve endings. Our evidence suggests that tachykinin release in response to antigen is provoked mainly by the release of kinins.
authors.affiliation: Cardiovascular Research Institute, University of California, San Francisco.
authors.forename: F L
authors.initials: FL
authors.lastname: Ricciardolo
authors.forename: J A
authors.initials: JA
authors.lastname: Nadel
authors.forename: C
authors.initials: C
authors.lastname: Bertrand
authors.forename: I
authors.initials: I
authors.lastname: Yamawaki
authors.forename: B
authors.initials: B
authors.lastname: Chan
authors.forename: P
authors.initials: P
authors.lastname: Geppetti
mesh_terms: D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects*; D002211:Capsaicin / Q000494:pharmacology; D005070:Evans Blue; D006020:Glycopeptides / Q000494:pharmacology; D006168:Guinea Pigs; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D066298:In Vitro Techniques; D007705:Kinins / Q000378:metabolism / Q000494:pharmacology*; D008297:Male; D009297:Nasal Mucosa / Q000098:blood supply / Q000187:drug effects* / Q000276:immunology; D009411:Nerve Endings / Q000187:drug effects; D064729:Neurokinin-1 Receptor Antagonists; D009475:Neurons, Afferent / Q000187:drug effects; D010047:Ovalbumin / Q000276:immunology; D011480:Protease Inhibitors / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology; D015320:Tachykinins / Q000494:pharmacology*
chemical_list: D001713:Biphenyl Compounds; D006020:Glycopeptides; D006993:Hypnotics and Sedatives; D007705:Kinins; D064729:Neurokinin-1 Receptor Antagonists; D011480:Protease Inhibitors; D015320:Tachykinins; D013373:Substance P; D005070:Evans Blue; C065679:icatibant; D010047:Ovalbumin; D002211:Capsaicin; D001920:Bradykinin; C008890:phosphoramidon; C066892:CP 96345